TNG.PA (TNG.PA) Stock Analysis

Verdict: AVOID

Severe cash burn ($37.9M FCF) and persistent dilution outweigh Phase I/II clinical oncology upside near 52-week lows.

Investment score: 28/100

Is TNG.PA Stock Worth Reviewing? AI Model Thesis

The model generates an AVOID recommendation for Transgene S.A. ($0.8198 USD) due to critical cash burn ($37.89M FCF loss in 2025) and active share dilution.

Should You Buy or Sell TNG.PA Stock? Model Reasoning

The model advises avoiding Transgene S.A. due to acute cash runway risk and relentless share dilution. In 2025, operating cash burn was -$37.05M against a cash balance of just $6.66M, while total shares outstanding grew from 99.5M in 2022 to 144.5M in 2025. Until clinical milestones convert into funded licensing deals or non-dilutive capital, risk is severely tilted to the downside.

TNG.PA Fair Value & Price Target — AI Valuation

  • Model Assumptions: ["Annual operating cash burn remains at -$30M to -$38M over the next 12-24 months","No commercial product sales generated prior to 2027/2028","Share count expansion continues at 10-15% annually to fund ongoing research operations"]

TNG.PA Risk & Opportunity Analysis

Key Investment Risks

  • Immediate Equity Dilution and Cash Burn Runway — With 2025 FCF burn of -$37.89M and year-end cash of $6.656M, cash runway is limited to a few months without immediate capital calls or asset sales, making near-term equity dilution almost guaranteed.
  • Binary Clinical Trial Failure Risks — Failure or equivocal safety/efficacy data in TG4050 Phase I or TG4001 Phase II trials would eliminate the core valuation driver for the entire enterprise.
  • Liquidity Risk and Price Slippage — Average trading volume is low, exposing holders to steep price declines and illiquidity slippage if institutional holders liquidate positions.
  • Partner Termination or Delay Risk — Partnering agreements with AstraZeneca or Merck KGaA could be terminated or restructured without substantial milestone execution, removing primary non-dilutive funding paths.

Growth Opportunities & Upside Drivers

  • Phase I/II Clinical Milestones for TG4050 and TG4001 — Positive Phase II data readouts in HPV-positive cancers or personalized head & neck vaccine candidates could trigger multi-bagger clinical re-ratings or major pharma licensing deals before Q4 2026.
  • Strategic Pharma Partnerships (AstraZeneca, Merck KGaA, NEC) — Existing collaborations could expand into upfront cash milestone payments or co-development deals, mitigating cash burn without further equity dilution.
  • Euronext Paris Speculative Rebound Potential — With the stock 51.9% below its 52-week high ($1.703 USD) and trading close to historic support ($0.8005 USD), positive news triggers short-term technical bounces (e.g., +12.5% move on Sept 3, 2026).
  • Debt-Free Balance Sheet Structure — With $0 total debt reported at end of 2025, the company retains asset flexibility and clean capital structure if licensing partner funding materializes.

TNG.PA Action Plan — Entry, Exit and Stop Loss from the Model View

moderate

    aggressive

      conservative

        Frequently Asked Questions About TNG.PA (TNG.PA)

        Is TNG.PA stock a good investment?

        The cached TradeMates AI model rates TNG.PA as AVOID with an investment score of 28/100. The model generates an AVOID recommendation for Transgene S.A. ($0.8198 USD) due to critical cash burn ($37.89M FCF loss in 2025) and active share dilution. This is algorithmic model output, not personal investment advice.

        Does TNG.PA pay a dividend?

        The cached stock data on this page does not show a positive dividend yield for TNG.PA. Dividend status can change, so verify the latest company filings before relying on income assumptions.

        What does TNG.PA stock do?

        Clinical-stage biotechnology platform company developing therapeutic cancer vaccines (myvac) and targeted oncolytic viruses (Invir.IO), generating revenue primarily through partner research collaborations, technology licenses, and government research grants.

        What is TNG.PA stock's price target?

        This cached page does not contain a precise model fair value for TNG.PA.

        Is TNG.PA stock a buy?

        The TradeMates model verdict for TNG.PA is AVOID with an investment score of 28/100. Treat this as a model signal to review, not a personal buy recommendation.

        Is TNG.PA a good dividend stock?

        TNG.PA is not presented as a dividend idea on this cached TradeMates page because no positive dividend yield is available in the cached data.

        View the full interactive analysis